Recent developments in the systemic therapy of advanced gastroesophageal malignancies

Bibliography

• PARKIN DM, BRAY F, FERLAY J, PISANI P: Global cancer statistics, 2002. CA Cancer J. Clin. (2005) 55:74-108.
   PubMed Web of Science ®Google Scholar
• CREW KD, NEUGUT AI: Epidemiology of upper gastrointestinal malignancies. Semin. Oncol. (2004) 31:450-464.
   PubMed Web of Science ®Google Scholar
• MURAD AM, SANTIAGO FF, PETROIANU A, ROCHA PR, RODRIGUES MA, RAUSCH M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. (1993) 72:37-41.
   PubMed Web of Science ®Google Scholar
• PYRHÔNEN S, KUITUNEN T, NYANDOTO P, KOURI M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer. (1995) 71:587-591.
   PubMed Web of Science ®Google Scholar
• GLIMELIUS B, EKSTROM K, HOFFMAN K et al.: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. (1997) 8:163-168.
   PubMed Web of Science ®Google Scholar
• SCHEITHAUER W, KOMEK G, ZEH B et al.: Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial. Proceedings of the Second International Conference on Biology, Prevention, and Treatment of GI Malignancy (1995):68 (Abstract).
   Google Scholar
• WILS JA, KLEIN HO, WAGENER DJ et al.: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. (1991) 9:827-831.
   PubMed Web of Science ®Google Scholar
• VANHOEFER U, ROUGIER P, WILKE H et al.: Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. (2000) 18:2648-2657.
   PubMed Web of Science ®Google Scholar
• WEBB A, CUNNINGHAM D, SCARFFE JH et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. (1997) 15:261-267.
   PubMed Web of Science ®Google Scholar
• ROSS P, NICOLSON M, CUNNINGHAM D et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. (2002) 20:1996-2004.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J, CLAVEL M, CHEVALIER B: Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol. (1994) 5:495-505.
   PubMed Web of Science ®Google Scholar
• CASCINU S, GRAZIANO F, CARDARELLI N et al.: Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs (1998) 9:307-310.
   PubMed Web of Science ®Google Scholar
• AJANI JA, FAIRWEATHER J, DUMAS P, PATT YZ, PAZDUR R, MANSFIELD PF: Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J. Sci. Am. (1998) 4:269-274.
   PubMed Web of Science ®Google Scholar
• OHTSU A, BOKU N, TAMURA F et al.: An early Phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am. J. Clin. Oncol. (1998) 21:416-419.
   PubMed Web of Science ®Google Scholar
• YAMADA Y, SHIRAO K, OHTSU A et al.: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann. Oncol. (2001) 12:1133-1137.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI K, TADA M, HORIKOSHI N et al.: Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer (2002) 5:90-95.
   PubMedGoogle Scholar
• BABA H, EMI Y, KAKEJI Y et al.: Phase II study of weekly paclitaxel in patients with advanced gastric cancer in Japan. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4226 (Abstract).
   Google Scholar
• ARAI T, HAMAGUCHI T, SHIRAO K et al.: Weekly paclitaxel in patients with heavily treated advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:321 (Abstract 1291).
   Google Scholar
• CHO H, TSUBURAYA A, KOBAYASHI O, SAIRENJI M, MOTOHASHI H, IMADA T: Dose dense paclitaxel as second-line treatment for S-1 or UFT refractory gastric cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:357 (Abstract 1434).
   Google Scholar
• VANHOEFER U, HARSTRICK A, WILKE H et al.: Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur. J. Cancer. (1995) 31A:92-97.
   PubMedGoogle Scholar
• KORNEK GV, RADERER M, SCHULL B et al.: Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br. J. Cancer. (2002) 86:1858-1863.
   PubMed Web of Science ®Google Scholar
• PARK SR, OH DY, KIM DW et al.: A multi-center, late Phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol. Rep. (2004) 12:1059-1064.
   Google Scholar
• KIM I, SHIN J, KIM H, LEE M, KIM C: The low dose paclitaxel as first-line chemotherapy for metastatic or recurrent gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4171 (Abstract).
   Google Scholar
• LEE KW, OH DY, KIM JH et al.: Phase II study of low-dose paclitaxel and cisplatin as second-line therapy in 5-fluorouracil and platinum pretreated gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4194 (Abstract).
   Google Scholar
• BOKEMEYER C, LAMPE CS, CLEMENS MR et al.: A Phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs (1997) 8:396-399.
   PubMed Web of Science ®Google Scholar
• MURAD AM, PETROIANU A, GUIMARAES RC, ARAGAO BC, CABRAL LO, SCALABRINI-NETO AO: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am. J. Clin. Oncol. (1999) 22:580-586.
   PubMed Web of Science ®Google Scholar
• NINOMIYA M, KONDO K, KOJIMA H et al.: Phase II study of weekly paclitaxel plus 5-fluorouracil in patients with unresectable advanced or recurrent gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4075 (Abstract).
   Google Scholar
• PARK S, BANG S, CHO E et al.: Randomized Phase II trial of taxanes plus 5-fluorouracil for advanced gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4149 (Abstract).
   Google Scholar
• KUO S-H, HSU C-H, YEH K-H, LIN J-F, CHENG A-L: A Phase II study of weekly paclitaxel (taxol) and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (hdfl) in the treatment of advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:1280F (Abstract).
   Google Scholar
• KOLLMANNSBERGER C, QUIETZSCH D, HAAG C et al.: A Phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br. J. Cancer (2000) 83:458-462.
   PubMed Web of Science ®Google Scholar
• HONECKER F, KOLLMANNSBERGER C, QUIETZSCH D et al.: Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs (2002) 13:497-503.
   PubMed Web of Science ®Google Scholar
• KIM YH, SHIN SW, KIM BS et al.: Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer. (1999) 85:295-301.
   PubMed Web of Science ®Google Scholar
• CHUN HG, JEONG W, PATEL D, PUCCIO C, MITTELMAN A: A pilot trial of cisplatin plus continuous infusion (CI) of paclitaxel and 5-fluorouracil (5-FU) for adenocarcinoma of stomach and distal esophagus. Proc. Am. Soc. Clin. Oncol. (2002) 21:669 (Abstract).
   Google Scholar
• STATHOPOULOS GP, RIGATOS SK, FOUNTZILAS G, POLYZOS A, STATHOPOULOS JG: Paclitaxel and carboplatin in pretreated advanced gastric cancer: a Phase II study. Oncol. Rep. (2002) 9:89-92.
   PubMed Web of Science ®Google Scholar
• GADGEEL SM, SHIELDS AF, HEILBRUN LK et al.: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am. J. Clin. Oncol. (2003) 26:37-41.
   PubMed Web of Science ®Google Scholar
• CHANG HM, KIM TW, RYU BY et al.: Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum. Jpn J. Clin. Oncol. (2005) 35:251-255.
   PubMed Web of Science ®Google Scholar
• BAR-SELA G, TSALIC M, GAITINI D, STEINER M, HAIM N: Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity. Med. Oncol. (2003) 20:291-294.
   PubMed Web of Science ®Google Scholar
• SHARMA A, RAINA V, LOKHESHWAR N, DEO SV, SHUKLA NK, RATH GK: Multifractionated cisplatin, etoposide, and paclitaxel, (CEP) in unresectable gastric/gastro esophageal (GE) cancer: Phase II study. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4203.
   Google Scholar
• TANAKA M, OBATA T, SASAKI T: Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur. J. Cancer (1996) 32A:226-230.
   PubMed Web of Science ®Google Scholar
• SULKES A, SMYTH J, SESSA C et al.: Docetaxel (Taxotere) in advanced gastric cancer: results of a Phase II clinical trial. EORTC Early Clinical Trials Group. Br. J. Cancer (1994) 70:380-383.
   PubMed Web of Science ®Google Scholar
• MAVROUDIS D, KOUROUSIS C, ANDROULAKIS N et al.: Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a Phase II trial. Am. J. Clin. Oncol. (2000) 23:341-344.
   PubMed Web of Science ®Google Scholar
• GRAZIANO F, CATALANO V, BALDELLI AM et al.: A Phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann. Oncol. (2000) 11:1263-1266.
   PubMed Web of Science ®Google Scholar
• BANG YJ, KANG WK, KANG YK et al.: Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a Phase II trial. Jpn J. Clin. Oncol. (2002) 32:248-254.
   PubMed Web of Science ®Google Scholar
• GIULIANI F, GEBBIA V, DE VITA F et al.: Docetaxel as salvage therapy in advanced gastric cancer: a Phase II study of the Gruppo Oncologico Italia Meridionale (GOIM). Anti-Cancer Res. (2003) 23:4219-4222.
   PubMed Web of Science ®Google Scholar
• LEE J, RYU M, KANG H et al.: Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4220 (Abstract).
   Google Scholar
• CONSTENLA M, GARCIA-ARROYO R, LORENZO I, CARRETE N, CAMPOS B, PALACIOS P: Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a Phase II study. Gastric Cancer (2002) 5:142-147.
   PubMedGoogle Scholar
• THUSS-PATIENCE PC, KRETZSCHMAR A, REPP M et al.: Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized Phase II study. J. Clin. Oncol. (2005) 23:494-501.
   PubMed Web of Science ®Google Scholar
• CHUNG HC, JEUNG HC, RHA SY, NOH SH, ROH JK: Combination treatment of infusional 5-fluorouracil, low-dose leucovorin and docetaxel (flt) for advanced gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4144 (Abstract).
   Google Scholar
• NGUYEN S, FLESCH M, BENNAMOUN M et al.: Multicentric Phase II study of epirubicin and docetaxel as first line treatment for patients with advanced gastric cancer: a GERCOR study. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4062 (Abstract).
   Google Scholar
• WADLER S, EINZIG A, CATALANO P, BENSON A: Randomized Phase II trial of either fluorouracil (F), parenteral hydroxyurea (H), interferon-α2a (I) and filgrastim (G) or doxorubicin/docetaxel (AD) in patients (PTS) with advanced gastric cancer: Eastern Cooperative Oncology Group (ECOG) Study EST 6296. Proc. Am. Soc. Clin. Oncol. (2001) 20:Abstract 659.
   Google Scholar
• MAEDA S, SUGIURA T, SAIKAWA Y et al.: Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci. (2004) 95:679-684.
   PubMed Web of Science ®Google Scholar
• ROTH AD, MAIBACH R, MARTINELLI G et al.: Docetaxel (Taxotere)–cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann. Oncol. (2000) 11:301-306.
   PubMed Web of Science ®Google Scholar
• RIDWELSKI K, GEBAUER T, FAHLKE J et al.: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann. Oncol. (2001) 12:47-51.
   PubMed Web of Science ®Google Scholar
• KETTNER E, RIDWELSKI K, KEILHOLZ U et al.: Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer: results of two Phase II studies. Proc. Am. Soc. Clin. Oncol. (2001) 20:657 (Abstract).
   Google Scholar
• MITACHI Y, SAKATA Y, OHTSU A et al.: Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter Phase I/II study. Gastric Cancer (2002) 5:160-167.
   PubMedGoogle Scholar
• SCHULL B, KORNEK GV, SCHMID K et al.: Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer. Oncology (2003) 65:211-217.
   PubMed Web of Science ®Google Scholar
• PARK Y, PARK K, LEE J et al.: Phase II study of Docetaxel combined with Cisplatin in Advanced Gastric Cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4077 (Abstract).
   Google Scholar
• PARK SH, KANG WK, LEE HR et al.: Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am. J. Clin. Oncol. (2004) 27:477-480.
   PubMed Web of Science ®Google Scholar
• KUNISAKI C, AKIYAMA H, OTSUKA Y et al.: Second-line chemotherapy with combined docetaxel and cisplatin for patients with far advanced gastric carcinoma. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4214 (Abstract).
   Google Scholar
• FAHLKE J, RIDWELSKI K, SCHMIDT C et al.: Docetaxel–cisplatin (DC) versus 5-fluorouracil–leucovorin–cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: preliminary safety results of a Phase III study. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4045 (Abstract).
   Google Scholar
• MAIELLO E, GIULIANI F, ROMITO S et al.: Epirubicin (Epi), docetaxel (TXT), folinic acid (FA) and fluorouracil (FU) bolus and continuous infusion in the treatment of advanced gastric cancer. A multicenter Phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). Proc. Am. Soc. Clin. Oncol. (2003) 22:359 (Abstract 1440).
   Web of Science ®Google Scholar
• MURAD AM, VINHOLES J, SKARE N, LAGO S, PECEGO R, GARCIA R: A Phase II multicentric trial of docetaxel (Taxotere), 5-fluorouracil (5-FU) and epirubicin (EPI) in previously untreated advanced gastric cancer: a novel and effective regimen. Proc. Am. Soc. Clin. Oncol. (2002) 21:650 (Abstract).
   Google Scholar
• LEE SH, KANG WK, PARK J et al.: Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br. J. Cancer (2004) 91:18-22.
   PubMed Web of Science ®Google Scholar
• DI LAURO L, BELLI F, ARENA MG et al.: Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Ann. Oncol. (2005)
   PubMedGoogle Scholar
• PAPAKOSTAS P, XANTHAKIS J, TSAVDARIDIS D et al.: Intensive weekly chemotherapy for advanced gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4212 (Abstract).
   Google Scholar
• ELSAID AA, ELKERM Y: Final results of a randomized Phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4014 (Abstract).
   Google Scholar
• ROTH AD, MAIBACH R, FAZIO N et al.: 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)–cisplatin in advanced gastric carcinoma: a Phase I-II trial. Ann. Oncol. (2004) 15:759-764.
   PubMed Web of Science ®Google Scholar
• OH DY, KIM TY, KWON JH et al.: Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J. Clin. Oncol. (2005) 35:380-385.
   PubMed Web of Science ®Google Scholar
• LATIFZADEH SZ, ENTEZARI V, AKHAVANFARD S: Docetaxel, cisplatin, 5-flourouracil × 3 days (DCF3) compared to docetaxel, cisplatin, 5-flourouracil × 5 days (DCF5) chemotherapy for patients with metastatic or locally advanced, unresectable gastric carcinoma (MGC). J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4258 (Abstract).
   Google Scholar
• PARK SR, CHUN JH, KIM YW et al.: Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol. GI Symposium (2005) (Abstract 40).
   Google Scholar
• ROTH AD, MAIBACH R, FALK S et al.: Docetaxel–cisplatin–5FU (TCF) versus docetaxel–cisplatin (TC) versus epirubicin–cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4020 (Abstract).
   Google Scholar
• AJANI JA, FODOR MB, TJULANDIN SA et al.: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J. Clin. Oncol. (2005) 23:5660-5667.
   PubMed Web of Science ®Google Scholar
• MOISEYENKO VM, AJANI JA, TJULANDIN SA et al.: Final results of a randomized controlled Phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4002 (Abstract).
   Google Scholar
• LAVELLE F, BISSERY MC, ANDRE S, ROQUET F, RIOU JF: Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin. Oncol. (1996) 23:11-20.
   PubMed Web of Science ®Google Scholar
• KOHNE CH, CATANE R, KLEIN B et al.: Irinotecan is active in chemonaive patients with metastatic gastric cancer: a Phase II multicentric trial. Br. J. Cancer (2003) 89:997-1001.
   PubMed Web of Science ®Google Scholar
• ERLICHMAN C, GOLDBERG RM, MAHONEY MR et al.: A Phase II trial of CPT-11 in patients (pts) with advanced gastric or gastroesophageal (GE) junction adenocarcinoma (ADCA): a clinical and pharmacodynamic evaluation. A North Central Cancer Treatment Group (NCCTG) Study. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4026 (Abstract).
   Google Scholar
• ENZINGER P, KULKE M, CLARK J et al.: Phase II Trial of CPT-11 in previously untreated patients with advanced adenocarcinoma of the esophagus and stomach. Proc. Am. Soc. Clin. Oncol. (2000) 19:1243 (Abstract).
   Google Scholar
• CHUN JH, KIM HK, LEE JS et al.: Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J. Clin. Oncol. (2004) 34:8-13.
   PubMed Web of Science ®Google Scholar
• BOKU N, OHTSU A, SHIMADA Y et al.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. (1999) 17:319-323.
   PubMed Web of Science ®Google Scholar
• AJANI JA, BAKER J, PISTERS PW et al.: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a Phase II study. Cancer (2002) 94:641-646.
   PubMed Web of Science ®Google Scholar
• AJANI JA, BAKER J, PISTERS PW et al.: Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) (2002) 16:16-18.
   Google Scholar
• LIM WT, LIM ST, WONG NS, KOO WH: CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians. J. Chemother. (2003) 15:400-405.
   PubMed Web of Science ®Google Scholar
• KOIZUMI W, KURIHARA M, SATOH A et al.: Phase I/II study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anti-Cancer Res. (2005) 25:1257-1262.
   PubMed Web of Science ®Google Scholar
• PARK SH, CHOI EY, BANG SM et al.: Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs (2005) 16:621-625.
   PubMed Web of Science ®Google Scholar
• ALTINBAS M, ER O, OZKAN M et al.: Irinotecan plus cisplatin combination against metastatic gastric cancer: Phase II study. Med. Oncol. (2005) 22:153-160.
   PubMed Web of Science ®Google Scholar
• BAEK J, KIM J, SOHN S et al.: Phase II study of biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4072 (Abstract).
   Google Scholar
• JEUNG HC, NOH SH, LEE JI, CHUNG HC, RHA SY, ROH JK: Fractional weekly administration of irinotecan and cisplatin as a second-line treatment for advanced gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4079 (Abstract).
   Google Scholar
• IMAMURA H, FURUKAWA H, IKEDA M et al.: Phase II study of a combination of protracted infusion of irrinotecan and cisplatin for metastatic gastric cancer: a study by the Osaka Gastrointestinal Chemotherapy Study Group. Proc. Am. Soc. Clin. Oncol. (2002) 21:622 (Abstract).
   Google Scholar
• POZZO C, BARONE C, SZANTO J et al.: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol. (2004) 15:1773-1781.
   PubMed Web of Science ®Google Scholar
• DANK M, ZALUSKI J, BARONE C et al.: Randomized Phase III trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) versus CDDP + 5FU in 1st-line advanced gastric cancer patients. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4003 (Abstract).
   Google Scholar
• BLANKE CD, HALLER DG, BENSON AB et al.: A Phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann. Oncol. (2001) 12:1575-1580.
   PubMed Web of Science ®Google Scholar
• MOEHLER M, HAAS U, SIEBLER J et al.: Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs (2003) 14:645-650.
   PubMed Web of Science ®Google Scholar
• ASSERSOHN L, BROWN G, CUNNINGHAM D et al.: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann. Oncol. (2004) 15:64-69.
   Google Scholar
• KIM ST, KANG WK, KANG JH et al.: Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br. J. Cancer (2005) 92:1850-1854.
   PubMed Web of Science ®Google Scholar
• FINDLAY MPN, ACKLAND S, GEBSKI V et al.: Phase II study of irinotecan, leucovorin and 5FU (ILF) in advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:655 (Abstract).
   Google Scholar
• BOUCHE O, RAOUL JL, BONNETAIN F et al.: Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J. Clin. Oncol. (2004) 22:4319-4328.
   PubMed Web of Science ®Google Scholar
• MOEHLER M, EIMERMACHER A, SIEBLER J et al.: Randomised Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br. J. Cancer (2005) 92:2122-2128.
   PubMed Web of Science ®Google Scholar
• JATOI A, TIRONA MT, CHA SS et al.: A Phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int. J. Gastrointest. Cancer (2002) 32:115-123.
   PubMedGoogle Scholar
• PARK SR, CHUN JH, KIM YW et al.: Phase II trial of docetaxel and irinotecan in metastatic gastric carcinoma: preliminary results. Proc. Am. Soc. Clin. Oncol. GI Symposium (2005) (Abstract 32).
   Google Scholar
• ENRECH S, GONZALEZ E, MENDEZ M et al.: Docetaxel in combination with irinotecan (CPT-11) in locally advanced or metastatic gastric cancer. A Goti Cooperative Spanish Group Study. Proc. Am. Soc. Clin. Oncol. (2003) 22:362 (Abstract 1455).
   Google Scholar
• CHANG H-M, KIM T-W, YOOK JH et al.: Phase II study of irinotecan (I) and docetaxel (D) as a second line chemotherapy for patients with previously treated advanced gastric cancer (AGC). Proc. Am. Soc. Clin. Oncol. (2003) 22:328 (Abstract 1316).
   Google Scholar
• CHAN D, GEORGE S, ALLISON MA, ROSEN LS, ERAKLIS E, HECHT JR: A Phase II trial of irinotecan (CPT-11) and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Proc. Am. Soc. Clin. Oncol. (2002) 21:2230 (Abstract).
   Web of Science ®Google Scholar
• HAWKINS R, CUNNINGHAM D, SOERBYE H et al.: Randomized Phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc. Am. Soc. Clin. Oncol. (2003) 22:257 (Abstract 1032).
   Google Scholar
• ENZINGER PC, CLARK J, RYAN D et al.: Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4040 (Abstract).
   Google Scholar
• HAMAGUCHI T, OHTSU A, HYODO I et al.: A Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: the Japan Clinical Oncology Group trial (JCOG0109). J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4071 (Abstract).
   Google Scholar
• GIULIANI F, MAIELLO E, MOLICA S et al.: Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients. A Phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM). J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4235 (Abstract).
   Google Scholar
• SLATER S, SHAMASH J, WILSON P, GALLAGHER CJ, SLEVIN ML: Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers – a new active regimen. Br. J. Cancer (2002) 87:850-853.
   PubMed Web of Science ®Google Scholar
• RAYMOND E, FAIVRE S, WOYNAROWSKI JM, CHANEY SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. (1998) 25:4-12.
   PubMed Web of Science ®Google Scholar
• LOUVET C, ANDRE T, TIGAUD JM et al.: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. (2002) 20:4543-4548.
   Google Scholar
• AL-BATRAN SE, ATMACA A, HEGEWISCH-BECKER S et al.: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J. Clin. Oncol. (2004) 22:658-663.
   PubMed Web of Science ®Google Scholar
• CHAO Y, YEH KH, CHANG CJ et al.: Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br. J. Cancer (2004) 91:453-458.
   PubMed Web of Science ®Google Scholar
• DE VITA F, ORDITURA M, MATANO E et al.: A Phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br. J. Cancer (2005) 92:1644-1649.
   PubMed Web of Science ®Google Scholar
• LORDICK F, LORENZEN S, STOLLFUSS J et al.: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br. J. Cancer (2005) 93:190-194.
   PubMed Web of Science ®Google Scholar
• HWANG W, CHAO T, CHAO Y et al.: An open non-comparative Phase II trial of oxaliplatin in combination with 5-fluorouracil/leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol. GI Symposium (2005) (Abstract 55).
   Google Scholar
• CAVANNA L, ZANIBONI A, ARTIOLI F et al.: Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC). J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4068 (Abstract).
   Google Scholar
• IOP A, BONURA S, MANFREDI A, ARTIOLI F: Combination of oxaliplatin, 5-fluorouracil and folinic acid in advanced/metastatic gastric carcinoma. Proc. Am. Soc. Clin. Oncol. GI Symposium (2004) (Abstract 60).
   Google Scholar
• JIN M, CHEN Q, CHENG FQ et al.: Oxaliplatin (OXA) in combination with LV5FU2 in Chinese patients with advanced gastric cancer (AGC). Proc. Am. Soc. Clin. Oncol. (2002) 21:558 (Abstract).
   Google Scholar
• BANG Y-J, KANG Y-K, KANG W-K et al.: Phase II study of oxaliplatin, 5-fluorouracil and folinic acid in recurrent or metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:2249 (Abstract).
   Google Scholar
• AL-BATRAN S, STÖHLMACHER J, PROBST S et al.: Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first line therapy for patients with advanced gastric cancer; first interim analysis of a randomised multicenter Phase II study. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4015 (Abstract).
   Google Scholar
• KIM DY, KIM JH, LEE SH et al.: Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann. Oncol. (2003) 14:383-387.
   PubMed Web of Science ®Google Scholar
• CATALANO V, GRAZIANO F, SALVAGNI S et al.: Lack of resistance to oxaliplatin (L-OHP)-based chemotherapy in patients (pts) with advanced gastric cancer previously treated with cisplatin-containing regimens: preliminary results of a Phase II study. Proc. Am. Soc. Clin. Oncol. (2002) 21:2200 (Abstract).
   Google Scholar
• SCHINZARI G, D’ARGENTO E, QUIRINO M et al.: Docetaxel and oxaliplatin combination as second line treatment in patients with advanced gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4188 (Abstract).
   Google Scholar
• PAN H-M, ZHU N, LOU F et al.: A Phase II study of oxaliplatin with ELF regimen in patients with advanced gastric cancer. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4206 (Abstract).
   Google Scholar
• TANAKA R, ARIYAMA H, QIN B et al.: Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. Oncol. Rep. (2005) 14:683-688.
   PubMed Web of Science ®Google Scholar
• SOUGLAKOS J, SYRIGOS K, POTAMIANOU A et al.: Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre Phase II trial. Ann. Oncol. (2004) 15:1204-1209.
   PubMed Web of Science ®Google Scholar
• SUMPTER K, HARPER-WYNNE C, CUNNINGHAM D et al.: Report of two protocol planned interim analyses in a randomised multicentre Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br. J. Cancer (2005) 92:1976-1983.
   PubMed Web of Science ®Google Scholar
• KOIZUMI W, SAIGENJI K, UJIIE S, TERASHIMA M, SAKATA Y, TAGUCHI T: A pilot Phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology (2003) 64:232-236.
   PubMed Web of Science ®Google Scholar
• HONG YS, SONG SY, LEE SI et al.: A Phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann. Oncol. (2004) 15:1344-1347.
   PubMed Web of Science ®Google Scholar
• KONDO K, CHIN K, SAKAMOTO J et al.: A multicenter Phase II trial using 4-week cycles of capecitabine in advanced/metastatic gastric cancer (AGC). Proc. Am. Soc. Clin. Oncol. (2003) 22:321 (Abstract 1289).
   Google Scholar
• KIM TW, KANG YK, AHN JH et al.: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann. Oncol. (2002) 13:1893-1898.
   PubMed Web of Science ®Google Scholar
• KANG HJ, CHANG HM, KIM TW et al.: Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br. J. Cancer (2005) 92:246-251.
   PubMed Web of Science ®Google Scholar
• JIN M, SHEN L, HU B et al.: Capecitabine (X) combined with fractionated cisplatin (C) as first-line therapy in Chinese patients (pts) with advanced gastric carcinoma (AGC). J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4053 (Abstract).
   Google Scholar
• PARK YH, RYOO BY, CHOI SJ, KIM HT: A Phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br. J. Cancer (2004) 90:1329-1333.
   PubMed Web of Science ®Google Scholar
• CHUN JH, KIM HK, LEE JS et al.: Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am. J. Clin. Oncol. (2005) 28:188-194.
   PubMed Web of Science ®Google Scholar
• KIM JG, SOHN SK, KIM DH et al.: Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology (2005) 68:190-195.
   PubMed Web of Science ®Google Scholar
• CATALANO G, ORDITURA M, DIADEMA M, AURILIO G, CIARDIELLO F, DE VITA F: Phase II study of weekly docetaxel and capecitabine in patients with metastatic gastric cancer (GC). J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4207 (Abstract).
   Google Scholar
• KANG HJ, KIM TW, CHANG HM et al.: A Phase II study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4051 (Abstract).
   Google Scholar
• ASSERSOHN L, NORMAN AR, CHONG G et al.: Phase II trial evaluating capecitabine and irinotecan (CapeIri) in patients (pts) with esophago-gastric (E-G) carcinoma having progressed or relapsed within 3 months of platinum-based chemotherapy. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4170 (Abstract).
   Google Scholar
• PARK Y, KIM B, RYOO B, YANG S: Oxaliplatin and capecitabine combination chemotherapy for patients with advanced gastric carcinoma: a pilot study results. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4199 (Abstract).
   Google Scholar
• JATOI A, MURPHY B, FOSTER N et al.: Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia: a Phase II study from the North Central Cancer Treatment Group. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4059 (Abstract).
   Google Scholar
• CHO EK, LEE WK, IM SA et al.: A Phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology (2005) 68:333-340.
   PubMed Web of Science ®Google Scholar
• KIM YH, SHIN SW, KIM BS, PARK YT, KIM JG, KIM JS: A Phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. Oncology (Williston Park) (1997) 11:119-123.
   PubMedGoogle Scholar
• RAVAUD A, BORNER M, SCHELLENS JH et al.: UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) Phase II trial. Eur. J. Cancer (2001) 37:1642-1647.
   PubMed Web of Science ®Google Scholar
• SATO A, KURIHARA M, KOIZUMI W, TAKEDA, FUKUYAMA Y: A Phase II study of UFT plus cisplatin (UFTP) therapy in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:1087 (Abstract).
   Google Scholar
• KURIHARA M, IZUMI T, YOSHIDA S et al.: A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J. Cancer Res. (1991) 82:613-620.
   PubMedGoogle Scholar
• JIN M, YANG B, ZHANG W, WANG Y: High-dose mitomycin C-containing regimens in the treatment of advanced gastric cancer. Semin. Surg. Oncol. (1994) 10:114-116.
   PubMed Web of Science ®Google Scholar
• FELIU J, GONZALEZ BARON M, GARCIA-GIRON C et al.: Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A Phase II study of the ONCOPAZ Cooperative Group. Cancer (1996) 78:211-216.
   PubMed Web of Science ®Google Scholar
• CHAO Y, LI CP, CHAO TY et al.: An open, multi-center, Phase II clinical trial to evaluate efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer – preliminary report. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4156 (Abstract).
   Google Scholar
• HAYAKAWA M, MORISE K, CHIN K et al.: Combination chemotherapy with tegafur–uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer. Jpn J. Clin. Oncol. (1994) 24:282-288.
   PubMed Web of Science ®Google Scholar
• JEEN YT, YOON SY, SHIN SW et al.: Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer (2001) 91:2288-2293.
   PubMed Web of Science ®Google Scholar
• WOO IS, MOON DO H, SHIM BY et al.: A Phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. Jpn J. Clin. Oncol. (2005) 35:13-17.
   PubMed Web of Science ®Google Scholar
• FUENTES J, REINA JJ, BERNABE R et al.: A Phase II study using epirubicin, cisplatin and oral uracil-tegafur (ECU) in patients with advanced gastric cancer (AGC). Proc. Am. Soc. Clin. Oncol. (2003) 22:349 (Abstract 1400).
   Web of Science ®Google Scholar
• OH SC, PARK KH, CHOI IK et al.: Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer. Br. J. Cancer (2005) 92:827-831.
   PubMed Web of Science ®Google Scholar
• OHTSU A, SHIMADA Y, SHIRAO K et al.: Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. (2003) 21:54-59.
   Google Scholar
• SAKATA Y, OHTSU A, HORIKOSHI N, SUGIMACHI K, MITACHI Y, TAGUCHI T: Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer (1998) 34:1715-1720.
   PubMed Web of Science ®Google Scholar
• KOIZUMI W, KURIHARA M, NAKANO S, HASEGAWA K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology (2000) 58:191-197.
   PubMed Web of Science ®Google Scholar
• CHOLLET P, SCHOFFSKI P, WEIGANG-KOHLER K et al.: Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur. J. Cancer (2003) 39:1264-1270.
   PubMed Web of Science ®Google Scholar
• IWASE H, SHIMADA M, TSUZUKI T et al.: A Phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer. Anti-Cancer Res. (2005) 25:1297-301.
   PubMed Web of Science ®Google Scholar
• AJANI JA, PHAN A, YAO JC et al.: Multi-center Phase II study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC). J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4024 (Abstract).
   Google Scholar
• KOIZUMI W, TANABE S, SAIGENJI K et al.: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br. J. Cancer (2003) 89:2207-2212.
   PubMed Web of Science ®Google Scholar
• YOSHIDA K, TOGE T, NINOMIYA M et al.: Phase II study of S-1 and docetaxel combination in advanced or recurrent gastric cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4049 (Abstract).
   Google Scholar
• HYODO I, YAMAGUCHI K, KOIZUMI W et al.: Phase I/II study of docetaxel (DOC) and S-1 for patients (pts) with advanced gastric cancer (AGC). J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4064 (Abstract).
   Google Scholar
• JACKMAN AL, TAYLOR GA, GIBSON W et al.: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. (1991) 51:5579-5586.
   PubMed Web of Science ®Google Scholar
• JACKMAN AL, FARRUGIA DC, GIBSON W et al.: ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer (1995) 31A:1277-1282.
   PubMed Web of Science ®Google Scholar
• BEALE P, JUDSON I, HANWELL J et al.: Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother. Pharmacol. (1998) 42:71-76.
   PubMed Web of Science ®Google Scholar
• JUDSON I, MAUGHAN T, BEALE P et al.: Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). Br. J. Cancer (1998) 78:1188-1193.
   PubMed Web of Science ®Google Scholar
• MEROPOL NJ, PAZDUR R, VINCENT M, WILLSON JK, KELSEN DP, DOUGLASS HO Jr: Phase II study of ZD1694 in patients with advanced gastric cancer. Am. J. Clin. Oncol. (1996) 19:628-630.
   PubMed Web of Science ®Google Scholar
• MacKAY HJ, McINNES A, PAUL J et al.: A Phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Ann. Oncol. (2001) 12:1407-1410.
   PubMed Web of Science ®Google Scholar
• CHACÓN JI, FELIÚ J, SAENZ JAG et al.: Oxaliplatin (Ox) and raltitrexed (Ral) as first line treatment for locally advanced and metastatic gastric adenocarcinoma: results of an ONCOPAZ Phase II trial (OPHA 0141). J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4213 (Abstract).
   Google Scholar
• SCHMID KE, KORNEK GV, SCHULL B et al.: Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie (2003) 26:255-258.
   PubMed Web of Science ®Google Scholar
• CHRISTMAN K, KELSEN D, SALTZ L, TARASSOFF PG: Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer (1994) 73:5-7.
   PubMed Web of Science ®Google Scholar
• SESSA C, AAMDAL S, WOLFF I et al.: Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials Group. Ann. Oncol. (1994) 5:471-472.
   PubMed Web of Science ®Google Scholar
• DE LANGE SM, VAN GROENINGEN CJ, KROEP JR et al.: Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann. Oncol. (2004) 15:484-488.
   PubMed Web of Science ®Google Scholar
• CORREALE P, FULFARO F, MARSILI S et al.: Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. Cancer Chemother. Pharmacol. (2005) 56(6):563-568.
   PubMed Web of Science ®Google Scholar
• KIM NK, IM SA, KIM DW et al.: Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer (1999) 86:1109-1115.
   Google Scholar
• KIM N, BANG Y-J, HEO D et al.: SKI 2053R and 5-fluorouracil (5-fu) in advanced gastric adenocarcinoma: Phase II clinical trial. Proc. Am. Soc. Clin. Oncol. (2000) 19:1277 (Abstract).
   Google Scholar
• THOMAS AL, O’BYRNE K, FURBER L, JEFFERY K, STEWARD WP: A Phase II study of caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer. Cancer Chemother. Pharmacol. (2001) 48:266-268.
   PubMed Web of Science ®Google Scholar
• GNAD-VOGT SU, HOFHEINZ RD, SAUSSELE S et al.: Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a Phase II trial. Anticancer Drugs (2005) 16:435-440.
   PubMed Web of Science ®Google Scholar
• BAJETTA E, CELIO L, BUZZONI R et al.: Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann. Oncol. (2003) 14:1543-1548.
   PubMed Web of Science ®Google Scholar
• FALK SJ, ANTHONEY A, EATOCK M et al.: Phase II pharmacokinetic (PK) and pharmacodynamic (PD) study of OSI-7904L in previously untreated patients (pts) with advanced gastric or gastroesophageal junction cancer (G/GEJC). J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4042 (Abstract).
   Google Scholar
• EBRAHIMI B, PHAN A, YAO JC et al.: Phase II clinical trial of Rubitecan against advanced gastric adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (2002) 21:596 (Abstract).
   Google Scholar
• BECERRA CR, TAKIMOTO C, AJANI JA et al.: A Phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4126 (Abstract).
   Google Scholar
• SCOTT LC, EVANS T, YAO JC et al.: Pegamotecan (EZ-246), a novel pegylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: preliminary results of a single-agent Phase II study. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4030 (Abstract).
   Google Scholar
• BOYER MJ, MOORE M, LEICHMAN L et al.: Phase II study of novel taxane BMS-184476 in previously treated patients with advanced adenocarcinoma involving the stomach or gastroesophageal (GE) junction. Proc. Am. Soc. Clin. Oncol. (2002) 21:591 (Abstract).
   Web of Science ®Google Scholar
• AJANI JA, SHAH MA, BOKEMEYER C et al.: Phase II study of the novel epothilone BMS-247550 in patients (pts) with metastatic gastric adenocarcinoma previously treated with a taxane. Proc. Am. Soc. Clin. Oncol. (2002) 21:619 (Abstract).
   Google Scholar
• LEVARD H, POULIQUEN X, HAY JM et al.: 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur. J. Surg. (1998) 164:849-857.
   PubMedGoogle Scholar
• TEBBUTT NC, NORMAN A, CUNNINGHAM D et al.: A multicentre, randomised Phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann. Oncol. (2002) 13:1568-1575.
   PubMed Web of Science ®Google Scholar
• BLEIBERG H, CONROY T, PAILLOT B et al.: Randomised Phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur. J. Cancer (1997) 33:1216-1220.
   PubMed Web of Science ®Google Scholar
• AJANI JA, ILSON DH, DAUGHERTY K, PAZDUR R, LYNCH PM, KELSEN DP: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J. Natl. Cancer Inst. (1994) 86:1086-1091.
   PubMed Web of Science ®Google Scholar
• ANDERSON SE, O’REILLY EM, KELSEN DP, ILSON DH: Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest. (2003) 21:512-516.
   PubMed Web of Science ®Google Scholar
• KELSEN D, ILSON D, WADLEIGH R, LEICHMANN L: A Phase II multi-center trial of paclitaxel (P) [Taxol] as a weekly one-hour infusion in advanced esophageal cancer (EC). Proc. Am. Soc. Clin. Oncol. (2000) 19:1266 (Abstract).
   Web of Science ®Google Scholar
• PETRASCH S, WELT A, REINACHER A, GRAEVEN U, KONIG M, SCHMIEGEL W: Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br. J. Cancer (1998) 78:511-514.
   PubMed Web of Science ®Google Scholar
• ILSON DH, FORASTIERE A, ARQUETTE M et al.: A Phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J. (2000) 6:316-323.
   PubMed Web of Science ®Google Scholar
• POLEE MB, ESKENS FA, VAN DER BURG ME et al.: Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br. J. Cancer (2002) 86:669-673.
   PubMed Web of Science ®Google Scholar
• CHO S, CHUNG I, YANG D et al.: Phase II study of paclitaxel and cisplatin for metastatic or recurrent esophageal cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4076 (Abstract).
   Google Scholar
• HUANG J, CAI GR, ZHANG JM, WANG WJ, DA CHU T, SUN Y: Phase II study of paclitaxel and cisplatin in advanced esophageal cancer: a Chinese esophageal cancer group. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4173 (Abstract).
   Google Scholar
• ILSON DH, AJANI J, BHALLA K et al.: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J. Clin. Oncol. (1998) 16:1826-1834.
   PubMed Web of Science ®Google Scholar
• LIN C, HSU C, YEH K et al.: A Phase II study using multi-fractionation of paclitaxel and cisplatin by twice weekly schedule, plus weekly 24-hour infusion of high-dose 5-fluorouacil and leucovorin (twice weekly TP-HDFL) in the treatment of metastatic or recurrent esophageal cancer: the final report. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4078 (Abstract).
   Google Scholar
• EINZIG AI, NEUBERG D, REMICK SC et al.: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med. Oncol. (1996) 13:87-93.
   PubMed Web of Science ®Google Scholar
• HEATH EI, URBA S, MARSHALL J, PIANTADOSI S, FORASTIERE AA: Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest. New Drugs (2002) 20:95-99.
   PubMed Web of Science ®Google Scholar
• MURO K, HAMAGUCHI T, OHTSU A et al.: A Phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann. Oncol. (2004) 15:955-959.
   PubMed Web of Science ®Google Scholar
• METGES J-P, HENNEQUIN C, YCHOU M et al.: Docetaxel (DOC) as a second line chemotherapy in metastatic esophageal cancer (MEC): a French study. Proc. Am. Soc. Clin. Oncol. (2001) 20:635 (Abstract).
   Google Scholar
• ALBERTSSON M, FAGERBERG J, JACOBSEN A-B et al.: Preliminary results of a Phase II study with Taxotere (docetaxel) in patients with primary untreated or recurrent oesophagus cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:1218 (Abstract).
   Google Scholar
• SLABBER C, FALKSON C, MUSI NN, WILM B: A Phase II study of docetaxel in advanced, inoperable squamous carcinoma of the esophagus. Proc. Am. Soc. Clin. Oncol. (1999) 18:1151 (Abstract).
   Google Scholar
• LIN L-S, HECHT J: A Phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction. Proc. Am. Soc. Clin. Oncol. (2000) 19:1130 (Abstract).
   Google Scholar
• ILSON DH, SALTZ L, ENZINGER P et al.: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. (1999) 17:3270-3275.
   PubMed Web of Science ®Google Scholar
• ILSON DH, GRAHAM C, STEINBRENNER L, FLOOD W: A multicenter Phase II trial of weekly irinotecan and cisplatin in advanced esophageal and GE junction cancer. Proc. Am. Soc. Clin. Oncol. GI Symposium (2004) (Abstract 13).
   Google Scholar
• LORDICK F, VON SCHILLING C, BERNHARD H, HENNIG M, BREDENKAMP R, PESCHEL C: Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br. J. Cancer (2003) 89:630-633.
   PubMed Web of Science ®Google Scholar
• BURTNESS B, GIBSON MK, LACY J et al.: Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4070 (Abstract).
   Google Scholar
• VILLALONA MA, BEKAII-SAAB T, BURAK W et al.: Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE junction adenocarcinomas. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4027 (Abstract).
   Google Scholar
• LIVINGSTON RB, EDWARDS J, GOLD PJ: Phase II trial of irinotecan (CPT-11) and mitomycin C (MMC) in the treatment of metastatic esophageal cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:292 (Abstract 1171).
   Google Scholar
• SANDLER AB, KINDLER HL, EINHORN LH et al.: Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann. Oncol. (2000) 11:1161-1164.
   PubMed Web of Science ®Google Scholar
• URBA SG, CHANSKY K, VANVELDHUIZEN PJ et al.: Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest. New Drugs (2004) 22:91-97.
   PubMed Web of Science ®Google Scholar
• KROEP JR, PINEDO HM, GIACCONE G, VAN BOCHOVE A, PETERS GJ, VAN GROENINGEN CJ: Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann. Oncol. (2004) 15:230-235.
   PubMedGoogle Scholar
• SCULLIN P, MILLAR J, DUNLOP D et al.: A Phase II trial of gemcitabine (gem) and cisplatin (cis) in advanced esophageal cancer (AEC). J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4034 (Abstract).
   Google Scholar
• PIPP M, MULKERIN D, WARREN D, HOTCHKIS W, BERLIN J, THOMAS JP: A Phase II trial of gemcitabine and 5-fluoruracil in advanced esophageal cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:630 (Abstract).
   Web of Science ®Google Scholar
• HILBIG A, STIELER J, PELZER U et al.: Phase II study of gemcitabine, cisplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) in patients with inoperable esophageal cancer (IEC). J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4238 (Abstract).
   Google Scholar
• WILLIAMSON SK, McCOY S, ABBRUZZESE JL: SWOG 0101: evaluation of gemcitabine and irinotecan in esophageal cancer. Proc. Am. Soc. Clin. Oncol. GI Symposium (2004) (Abstract 25).
   Google Scholar
• LEE J, IM Y, KANG J et al.: Phase II study of capecitabine and cisplatin as first-line therapy in patients with recurrent or metastatic esophageal carcinoma. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4221 (Abstract).
   Google Scholar
• LORENZEN S, DUYSTER J, LERSCH C et al.: Three-weekly docetaxel (T) plus capecitabine (X) in 1st and 2nd line metastatic esophageal cancer (MEC): final results of the Phase II DACAPO trial. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4142 (Abstract).
   Google Scholar
• MAUER AM, KRAUT EH, KRAUSS SA et al.: Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann. Oncol. (2005) 16:1320-1325.
   PubMed Web of Science ®Google Scholar
• KAECHELE V, SEUFFERLEIN T, HÖHLER T, MÖHLER M, LUTZ MP, ADLER G: Oxaliplatin and paclitaxel in inoperable cancer of the esophagus and the gastro-esophogeal junction – results of a Phase I/II study. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4229 (Abstract).
   Google Scholar
• YOSHIOKA T, GAMOH M, SHINEHA R et al.: A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. Intern. Med. (1999) 38:844-848.
   PubMed Web of Science ®Google Scholar
• MURO K, ANDO N, NISHIMAKI T et al.: A Phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: the Japan Clinical Oncology Group (JCOG) trial (JCOG 9905). Proc. Am. Soc. Clin. Oncol. (2003) 22:277 (Abstract 1112).
   Web of Science ®Google Scholar
• CIARDIELLO F, TORTORA G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur. J. Cancer (2003) 39:1348-1354.
   PubMed Web of Science ®Google Scholar
• FERRY DR, ANDERSON M, BEDDOWS K, MAYER P, PRICE L, JANKOWSKI J: Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4021 (Abstract).
   Google Scholar
• VAN GROENINGEN C, RICHEL D, GIACCONE G: Gefitinib Phase II study in second-line treatment of advanced esophageal cancer. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4022 (Abstract).
   Google Scholar
• ADELSTEIN DJ, RYBICKI LA, CARROLL MA, RICE TW, MEKHAIL T: Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4054 (Abstract).
   Google Scholar
• VERVENNE WL, BOLLEN JM, BERGMAN JJGHM et al.: Evaluation of the antitumor activity of gefitinib (ZD1839) in combination with celecoxib in patients with advanced esophageal cancer. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4054 (Abstract).
   Google Scholar
• DOI T, KOIZUMI W, SIENA S et al.: Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:258 (Abstract 1036).
   Google Scholar
• ZIMMERMANN KC, SARBIA M, WEBER AA, BORCHARD F, GABBERT HE, SCHROR K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. (1999) 59:198-204.
   PubMed Web of Science ®Google Scholar
• SOUZA RF, SHEWMAKE K, BEER DG, CRYER B, SPECHLER SJ: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. (2000) 60:5767-5772.
   PubMed Web of Science ®Google Scholar
• TEW WP, SHAH M, SCHWARTZ G, KELSEN D, ILSON DH: Phase II trial of erlotonib for second-line treatment in advanced esophageal cancer. Proc. Am. Soc. Clin. Oncol. GI Symposium (2005) (Abstract 5).
   Google Scholar
• DRAGOVICH T, McCOY S, URBA SG et al.: SWOG 0127: Phase II trial of erlotinib in gej and gastric adenocarcinomas. Proc. Am. Soc. Clin. Oncol. GI Symposium (2005) (Abstract 49).
   Google Scholar
• RAO S, STARLING N, BENSON M et al.: Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4028 (Abstract).
   Google Scholar
• ROSS JS, McKENNA BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. (2001) 19:554-568.
   PubMed Web of Science ®Google Scholar
• TANNER M, HOLLMEN M, JUNTTILA TT et al.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. (2005) 16:273-278.
   PubMed Web of Science ®Google Scholar
• MATSUI Y, INOMATA M, TOJIGAMORI M, SONODA K, SHIRAISHI N, KITANO S: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int. J. Oncol. (2005) 27:681-685.
   PubMed Web of Science ®Google Scholar
• CORLESS CL, HEINRICH MC, DIMITRIJEVIC S, DIRNHOFER S, NIKOLOVA Z, FLETCHER JA: Correlation of imatinib response with activation of KIT and PDGF receptors in a variety of cancers: results of the CSTIB2225 trial. Proc. Am. Soc. Clin. Oncol. (2003) 22:195 (Abstract 783).
   Google Scholar
• KRUG LM, CRAPANZANO JP, AZZOLI CG et al.: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial. Cancer (2005) 103:2128-2131.
   PubMed Web of Science ®Google Scholar
• DY GK, MILLER AA, MANDREKAR SJ et al.: A Phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann. Oncol. (2005) 16:1811-1816.
   PubMed Web of Science ®Google Scholar
• KHAMLY K, JEFFORD M, MICHAEL M, ZALCBERG J: Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opin. Investig. Drugs (2005) 14:607-628.
   PubMed Web of Science ®Google Scholar
• SHAH MA, ILSON D, RAMANATHAN RK et al.: A multicenter Phase II study of irinotecan(CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23:4025 (Abstract).
   Google Scholar
• ILSON D, SHAH M, O’REILLY E et al.: A Phase II trial of weekly one hour paclitaxel followed by bryostatin-1 in patients with advanced esophageal cancer: an active new drug combination. Proc. Am. Soc. Clin. Oncol. (2001) 20:633 (Abstract).
   Google Scholar
• CHANG BB, BLEYER AW, FAUST J, YAO J, CRAIG C, AJANI JA: Phase II study of bryostatin-1 (NSC 339555) plus paclitaxel in patients with metastatic or unresectable locally advanced adenocarcinoma of stomach or gastroesophageal junction. Proc. Am. Soc. Clin. Oncol. (2003) 22:264 (Abstract 1060).
   Google Scholar
• SCHRUMP DS, MATTHEWS W, CHEN GA, MIXON A, ALTORKI NK: Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin. Cancer Res.. (1998) 4:2885-2890.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GK, ILSON D, SALTZ L et al.: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol. (2001) 19:1985-1992.
   PubMed Web of Science ®Google Scholar
• RATHKOPF DE, ILSON DH, YI S, WINKELMANN J, KELSEN DP, SCHWARTZ GK: A Phase II trial of sequential paclitaxel and flavopiridol in patients with metastatic paclitaxel-refractory esophageal cancer. Proc. Am. Soc. Clin. Oncol. GI Symposium (2004) (Abstract 67).
   Google Scholar
• SHAH MA, HOLEN K, SINGH D et al.: A multicenter, two-stage, Phase II study of PS-341 in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Proc. Am. Soc. Clin. Oncol. GI Symposium (2005) (Abstract 41).
   Google Scholar
• OCEAN AJ, SCHNOLL-SUSSMAN F, CHEN X, HOLLOWAY S, WRIGHT J, WADLER S: Phase II study of PS-341 (VELCADE, bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Proc. Am. Soc. Clin. Oncol. GI Symposium (2005) (Abstract 31).
   Google Scholar
• BRAMHALL SR, HALLISSEY MT, WHITING J et al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer (2002) 86:1864-1870.
   PubMed Web of Science ®Google Scholar
• KIM R, EMI M, TANABE K, TOGE T: Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer (2004) 101:2177-2186.
   PubMed Web of Science ®Google Scholar
• VOLLMERS HP, HENSEL F, HERMANN R et al.: Tumor-specific apoptosis induced by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer. Oncol. Rep. (1998) 5:35-40.
   PubMed Web of Science ®Google Scholar
• HENSEL F, HERMANN R, SCHUBERT C et al.: Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res. (1999) 59:5299-306.
   PubMed Web of Science ®Google Scholar
• GILLIAM AD, WATSON SA, HENWOOD M et al.: A Phase II study of G17DT in gastric carcinoma. Eur. J. Surg. Oncol. (2004) 30:536-543.
   PubMed Web of Science ®Google Scholar
• MICHAELI D, HECHT JR, OORTGIESEN M, EDULJEE A, PERKINS WD, AJANI JA: Final data of the multicenter Phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in chemonaive patients with locally recurrent or metastatic gastric and gastroesophageal cancer. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (2004) 22:4048 (Abstract).
   Google Scholar